Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Chi

Showing results (231-240 of 410) with videos related to

Pageof 41
Sort By:
European Urology|September 24, 2024
Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE TrialDana E Rathkopf, Guilhem Roubaud, Kim N Chi, et al.
Pediatric Blood & Cancer|February 1, 2014
Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: an analysis of the Surveillance Epidemiology and End Results (SEER) databasePratiti Bandopadhayay, Guillaume Bergthold, Wendy B London, et al.
The New England Journal of Medicine|June 6, 2017
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate CancerKarim Fizazi, NamPhuong Tran, Luis Fein, et al.
Pediatric Blood & Cancer|July 29, 2006
Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescueStergios Zacharoulis, Adam Levy, Susan N Chi, et al.
Journal of Clinical Pharmacology|June 23, 2015
Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancerKim N Chi, Jennifer Spratlin, Christian Kollmannsberger, et al.
The Lancet. Oncology|January 13, 2018
Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trialKim N Chi, Andrew Protheroe, Alfredo Rodríguez-Antolín, et al.
Journal of Neuro-Oncology|April 25, 2012
Sleep dysfunction in long term survivors of craniopharyngiomaPeter E Manley, Kiera McKendrick, Megan McGillicudy, et al.
Asian Journal of Andrology|July 14, 2021
Apalutamide for patients with metastatic castrationsensitive prostate cancer in East Asia: a subgroup analysis of the TITAN trialByung Ha Chung, Jian Huang, Zhang-Qun Ye, et al.
Pediatric Blood & Cancer|March 5, 2025
Treatment Approach for Metastatic Intracranial Germinoma: A Multi-Institutional ExperiencePhoebe C Power, Kevin X Liu, Susan N Chi, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 21, 2012
A high-affinity, dimeric inhibitor of PSD-95 bivalently interacts with PDZ1-2 and protects against ischemic brain damageAnders Bach, Bettina H Clausen, Magda Møller, et al.
Pageof 41

Showing results (231-240 of 410) with videos related to

Sort By:
Pageof 41
European Urology|September 24, 2024
Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE TrialDana E Rathkopf, Guilhem Roubaud, Kim N Chi, et al.
Pediatric Blood & Cancer|February 1, 2014
Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: an analysis of the Surveillance Epidemiology and End Results (SEER) databasePratiti Bandopadhayay, Guillaume Bergthold, Wendy B London, et al.
The New England Journal of Medicine|June 6, 2017
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate CancerKarim Fizazi, NamPhuong Tran, Luis Fein, et al.
Pediatric Blood & Cancer|July 29, 2006
Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescueStergios Zacharoulis, Adam Levy, Susan N Chi, et al.
Journal of Clinical Pharmacology|June 23, 2015
Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancerKim N Chi, Jennifer Spratlin, Christian Kollmannsberger, et al.
The Lancet. Oncology|January 13, 2018
Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trialKim N Chi, Andrew Protheroe, Alfredo Rodríguez-Antolín, et al.
Journal of Neuro-Oncology|April 25, 2012
Sleep dysfunction in long term survivors of craniopharyngiomaPeter E Manley, Kiera McKendrick, Megan McGillicudy, et al.
Asian Journal of Andrology|July 14, 2021
Apalutamide for patients with metastatic castrationsensitive prostate cancer in East Asia: a subgroup analysis of the TITAN trialByung Ha Chung, Jian Huang, Zhang-Qun Ye, et al.
Pediatric Blood & Cancer|March 5, 2025
Treatment Approach for Metastatic Intracranial Germinoma: A Multi-Institutional ExperiencePhoebe C Power, Kevin X Liu, Susan N Chi, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 21, 2012
A high-affinity, dimeric inhibitor of PSD-95 bivalently interacts with PDZ1-2 and protects against ischemic brain damageAnders Bach, Bettina H Clausen, Magda Møller, et al.
Pageof 41